作者
Atheir I Abbas, Peter B Hedlund, Xi-Ping Huang, Thuy B Tran, Herbert Y Meltzer, Bryan L Roth
发表日期
2009/7
期刊
Psychopharmacology
卷号
205
页码范围
119-128
出版商
Springer-Verlag
简介
Rationale
Amisulpride is approved for clinical use in treating schizophrenia in a number of European countries and also for treating dysthymia, a mild form of depression, in Italy. Amisulpride has also been demonstrated to be an antidepressant for patients with major depression in many clinical trials. In part because of the selective D2/D3 receptor antagonist properties of amisulpride, it has long been widely assumed that dopaminergic modulation is the proximal event responsible for mediating its antidepressant and antipsychotic properties.
Objectives
The purpose of these studies was to determine if amisulpride’s antidepressant actions are mediated by off-target interactions with other receptors.
Materials and Methods
We performed experiments that: (1) examined the pharmacological profile of amisulpride at a large …
引用总数
学术搜索中的文章
AI Abbas, PB Hedlund, XP Huang, TB Tran, HY Meltzer… - Psychopharmacology, 2009